ArticleChinese medicine2021
Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications.
Article in Chinese medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Clinical evidence on integrated Chinese-Western medicine for perimenopausal syndrome.Integrative medicine research · 2026Article
- The impact of herbal medicine development on the population health in China.Scientific reports · 2026Article
- Navigating sociocultural practices and traditions in HIV management: a review of African cultural barriers to achieving sustainable development goal target 3.3.Frontiers in epidemiology · 2026Review
- Traditional Chinese medicine-induced cardiac adverse reactions: a critical review of current evidence, knowledge gaps, and pharmacovigilance strategies.Frontiers in pharmacology · 2026Review
- Regulatory frameworks and evidence requirements for traditional, complementary and integrative medicines.Bulletin of the World Health Organization · 2025Article
- Post-marketing safety evaluation of Guhong Injection: a multicenter, prospective real-world study of 30,000 cases in China.BMC complementary medicine and therapies · 2025Article
- Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation.Aesthetic plastic surgery · 2025Review
- Bridging traditional Chinese medicine and Alzheimer's disease: the pivotal role of gut microbiota in multitarget therapeutic mechanisms.Frontiers in pharmacology · 2025Review
- Policy and legal perspectives on the traditional Chinese medicine varietal protection system (TCMVPS): reform or abolition?Frontiers in pharmacology · 2025Review
- Research on the impact of traditional Chinese medicine registration innovation-oriented policies and enterprises performance: an empirical analysis based on listed enterprises in China.Frontiers in public health · 2025Article
- Regulatory effects of traditional Chinese medicine on the breast-cancer immune microenvironment.Frontiers in immunology · 2025Review
- Quantitative analysis of new drug registration policies for traditional Chinese medicine using the PMC index model.Frontiers in public health · 2025Article
- Pulsatilla Decoction and its bioactive component β-peltatin induce G2/M cell cycle arrest and apoptosis in pancreatic cancer.Chinese medicine · 2023Article
- Historical Aspects of Herbal Use and Comparison of Current Regulations of Herbal Products between Mexico, Canada and the United States of America.International journal of environmental research and public health · 2022Review
- A methodological framework for tackling confounding by indication when assessing the treatment effects of Chinese herbal injections in the real world.Journal of evidence-based medicine · 2022Article
- Market access of Chinese patent medicine products to healthcare security system in China: implications for international integration of traditional medicine into health systems.Chinese medicine · 2022Article
- Clinical and economic analysis of Gastrodin injection for dizziness or vertigo: a retrospective cohort study based on electronic health records in China.Chinese medicine · 2022Article
- Lignans fromEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Establishing a Regulatory Science System for Supervising the Application of Artificial Intelligence for Traditional Chinese Medicine: A Methodological Framework.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Study and exploration of the pharmacokinetics of traditional Tibetan medicine Ruyi Zhenbao tablets after single and long-term administration.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe National Medical Products Administration (NMPA) in China has set to advance the regulatory capacity of traditional Chinese medicines (TCMs) with the adoption of regulatory science (RS). However, the priority of actions at the interface of RS and TCMs were yet to be defined. This research aims to identify the priority areas and summarize core actions for advancing RS for traditional medicines in China.
methodsA mixed approach of documentary analysis of government policies, regulations and official information about TCMs regulation in China, and a scoping review of literature using 4 databases (PubMed, ScienceDirect, Scopus and CNKI) on major concerns in TCMs regulation was employed.
resultsTen priority areas in the development of TCM-related regulatory science in China have been identified, including: (1) modernizing the regulatory system with a holistic approach; (2) advancing the methodology for the quality control of TCMs; (3) fostering the control mechanism of TCMs manufacturing process; (4) improving clinical evaluation of TCMs and leveraging real world data; (5) re-evaluation of TCMs injection; (6) developing evaluation standards for classic TCMs formula; (7) harnessing diverse data to improve pharmacovigilance of TCMs; (8) evaluating the value of integrative medicine in clinical practice with scientific research; (9) advancing the regulatory capacity to encourage innovation in TCMs; and (10) advancing a vision of collaboration for RS development in TCMs.
conclusionsRS for TCMs in China encompasses revolution of operational procedures, advancement in science and technology, and cross-disciplinary collaborations. Such experiences could be integrated in the communications among drug regulatory authorities to promote standardized and scientific regulation of traditional medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.